US PI. Available from: https://www.novo-pi.com/rybelsus.pdf [Last accessed: April 2, 2023].
2.
ArodaVR, RosenstockJ, TerauchiY, et al.PIONEER 1: Randomized clinical trial of the efficacy and safety of oral semaglutide monotherapy in comparison with placebo in patients with type 2 diabetes. Diabetes Care, 2019; 42(9):1724–1732.
3.
RodbardHW, RosenstockJ, CananiLH, et al.Oral Semaglutide versus Empagliflozin in patients with type 2 diabetes uncontrolled on metformin: The pioneer 2 trial. Diabetes Care, 2019; 42(12):2272–2281; doi: 10.2337/dc19-0749
4.
RosenstockJ, AllisonD, BirkenfeldAL, et al.Effect of additional oral semaglutide vs sitagliptin on glycated hemoglobin in adults with type 2 diabetes uncontrolled with metformin alone or with sulfonylurea: The PIONEER 3 randomized clinical trial. JAMA, 2019; 321(15):1466–1480; doi: 10.1001/jama.2019.2942
5.
SinghAK, SinghR, MisraA. Oral semaglutide in type 2 diabetes mellitus: Comprehensive review, critical appraisal and clinical consideration of its use in India. Diabetes Metab Syndr, 2022; 16(3):102436; doi: 10.1016/j.dsx.2022.102436
6.
ClinicalTrials.gov Identifier: NCT04707469. Available from: https://www.clinicaltrials.gov/ct2/show/NCT04707469 [Last accessed: April 2, 2023].
7.
PIONEER Plus company announcement. Available from: https://www.globenewswire.com/news-release/2023/03/24/2634147/0/en/Oral-semaglutide-25-mg-and-50-mg-demonstrate-superior-reductions-in-HbA1c-and-body-weight-versus-14-mg-in-people-with-type-2-diabetes-in-the-PIONEER-PLUS-phase-3-trial.html [Last accessed: March 26, 2023].
